Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario

by Zacks Equity Research

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances

by Zacks Equity Research

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

by Zacks Equity Research

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Bruker's (BRKR) New Launches Drive Growth Amid FX Woes

by Zacks Equity Research

Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.

Here's Why Investors Should Hold Labcorp (LH) Stock for Now

by Zacks Equity Research

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Charles River (CRL) Forges Collaboration With Wheeler Bio

by Zacks Equity Research

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice

by Zacks Equity Research

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Ideas feature highlights: HCA Healthcare, DaVita and General Motors

by Zacks Equity Research

HCA Healthcare, DaVita and General Motors have been highlighted in this Investment Ideas article.

Earnings Estimates Moving Higher for DaVita HealthCare (DVA): Time to Buy?

by Zacks Equity Research

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Ethan Feller headshot

Markets Appear Vulnerable: Hideout in these 3 Top Ranked Defensive Stocks

by Ethan Feller

There are a number of bearish catalysts brewing... is it time to rotate into these defensive names?

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

by Zacks Equity Research

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Sight Sciences (SGHT) to Expand in Europe With New Launch

by Zacks Equity Research

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility

by Zacks Equity Research

GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.

Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

by Zacks Equity Research

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.

SenesTech (SNES) Expands in the Netherlands With Q-chem Deal

by Zacks Equity Research

SenesTech's (SNES) collaboration with Q-chem strategically aligns with the Netherlands' Integrated Pest Control program.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.

QIAGEN (QGEN) Earns Notable Recognitions in Sustainability

by Zacks Equity Research

QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.

National Vision (EYE) Hurt by Business Closure, Macro Woe

by Zacks Equity Research

National Vision's (EYE) impending termination of the long-term partnership with Walmart is likely to significantly impact its business.

Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).